ArticleBMC gastroenterology2026
Recurrence‑related factors after discontinuation of adjuvant imatinib in intermediate‑ and high‑risk GIST: a retrospective cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundGastrointestinal stromal tumors (GIST) are rare malignancies originating from mesenchymal tissue, with imatinib as the standard postoperative adjuvant therapy, especially for high-risk patients. However, recurrence after discontinuation remains an important clinical problem. This study aimed to identify factors influencing recurrence after imatinib discontinuation in intermediate- and high-risk GIST patients to guide individualized treatment strategies.
methodsPatients who underwent surgical resection and imatinib adjuvant therapy in Nanjing Drum Tower Hospital from 2011 to 2021 were retrospectively analyzed. In this study, end-point of tumor treatment ( EOOT ) recurrence-free survival ( RFS ) was used as the primary endpoint, which was defined as the time from the end of imatinib adjuvant therapy to the recurrence or metastasis of GIST. Univariate and multivariate Cox regression analyses, along with Kaplan-Meier curves, were used to assess the impact of clinicopathological factors.
resultsAmong 82 patients who discontinued imatinib, 19 experienced recurrence. Tumor site, tumor size, mitotic index, Ki-67 index, risk classification, and mutation type were significantly associated with recurrence (P < 0.05). Kaplan-Meier analysis showed that non-gastric tumors, larger size, high Ki-67, and mitotic index were linked to poorer EOOT RFS. In addition, while the EOOT RFS of patients who had been on the drug for more than 3 years was not statistically significantly different from those who had been on the drug for a shorter period of time, overall the RFS after discontinuation was longer in patients who had been on the drug for a longer period of time.
conclusionTumor size, mitotic index, Ki-67 index, and mutation type are key factors influencing recurrence after imatinib discontinuation. Prolonging the time of adjuvant therapy has an important prognostic improvement effect on high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.